{ }
Very Negative
Negative
Neutral
Positive
Very Positive
2025-03-292025-03-292025-03-302025-03-302025-03-312025-03-312025-04-012025-04-012025-04-022025-04-022025-04-032025-04-032025-04-042025-04-042524303523955169791713311012911596484942811036554400400320320240240160160808000
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-03-292025-03-292025-03-302025-03-302025-03-312025-03-312025-04-012025-04-012025-04-022025-04-022025-04-032025-04-032025-04-042025-04-0437294942614035216969725613812117613298921937362323400400320320240240160160808000
Download SVG
Download PNG
Download CSV

ubs maintains buy rating for chart industries with target of 225 dollars

UBS has reiterated its Buy rating on Chart Industries, maintaining a price target of $225, significantly above its current trading price of $142.54. Despite a projected EBITDA decline for Q1 2025 and a free cash flow deficit, the company is expected to resume deleveraging in Q2 2025, with revenue growth anticipated at 9% for the year. Moody’s has upgraded its corporate family rating, reflecting strong order growth, while Stifel also maintains a Buy rating with a target of $231.

bentley systems receives mixed analyst ratings amid institutional investor interest

Hedge funds and institutional investors hold 44.16% of Bentley Systems' stock, which provides infrastructure engineering software solutions globally. Analysts have mixed ratings on the stock, with a current average target price of $55.13, while shares recently traded down 2.3% to $38.78. Insider transactions revealed Director Keith A. Bentley sold 69,573 shares, reducing his stake slightly, while institutional investors have been adjusting their positions in the company.

ubs lowers atlassian price target to 230 maintains neutral rating

UBS has lowered its price target for Atlassian Corporation from $330 to $230 while maintaining a Neutral rating, citing budget scrutiny and modest seat expansion rates despite strong gross profit margins and expected net income growth. The stock has dropped over 10% recently but remains up 31% over the past six months. Analysts from KeyBanc and Stephens have differing views, with price targets of $365 and $255, respectively, reflecting confidence in Atlassian's growth potential ahead of its upcoming earnings report and Investor Day.

ubs maintains buy rating on warner music with 41 dollar target

UBS analyst Batya Levi has reaffirmed a Buy rating on Warner Music Group (NASDAQ: WMG) with a price target of $41, despite adjusting revenue forecasts due to softer advertising revenue. The company anticipates total revenues of $1.52 billion for the fiscal second quarter, reflecting a 2% year-over-year increase, while OIBDA is projected to reach $333 million, indicating a margin improvement. Recent earnings showed a decline in Recorded Music revenue but growth in Music Publishing, with analysts from Citi and FBN Securities also expressing optimism about the company's future prospects.

Trump to unveil tariff plan on Liberation Day amid market uncertainty

President Trump is set to unveil his tariff plan at a press conference in the White House Rose Garden, dubbing the day "Liberation Day." The plan aims to reduce U.S. dependence on foreign products and may include reciprocal tariffs, though details remain unclear.Market reactions could be significant, with potential for increased selling if the plan lacks clarity or if tariffs exceed expectations. Attention is particularly focused on the responses from the European Union and China, as uncertainty has already impacted consumer sentiment and raised recession fears.

dividend stocks poised for growth amid economic uncertainty in 2024

JPMorgan Chase & Co. is highlighted as a top choice for dividend capture in April, reflecting the resilience of dividend growth stocks during economic downturns. Analysts suggest that these stocks, particularly dividend aristocrats, can provide stability amid market volatility, with many currently trading at attractive valuations. The trend of increasing dividend payouts, especially in the tech sector, signals a promising outlook for income-focused investors.

ubs raises cryoport price target to eleven maintains buy rating

UBS has raised CryoPort's stock price target to $11 from $10, maintaining a Buy rating, as the company focuses on expanding its cell and gene therapy services. Following the divestiture of its CryoPDP subsidiary for $195 million, CryoPort is expected to enhance its financial position and growth potential, with improved earnings estimates for 2025 and 2026. The strategic move aligns with a strong liquidity position and aims to bolster CryoPort's market presence in the life sciences sector.

bank of america reports strong earnings and plans bond repayments ahead of schedule

Bank of America Corporation (NYSE:BAC) reported a Q4 net income of $6.7 billion, with a 15% revenue increase to $25.3 billion, driven by investment banking and trading fees. The bank plans to repay $3.5 billion in bonds ahead of schedule and will pay a $1.75 dividend on its preferred stock on April 25. BAC is favored by 18 billionaire investors, ranking it among the top financial stocks, as the sector shows strong momentum heading into 2025, bolstered by lower interest rates and increased M&A activity.

financial stocks poised for growth as mergers and acquisitions surge in 2025

Wells Fargo & Company (WFC) is among the top financial stocks favored by billionaires, benefiting from a strong financial sector that surged over 30% in 2024. With the Federal Reserve cutting rates, economic activity is expected to rise, despite some risks like loan defaults and commercial real estate exposure. As 2025 approaches, capital markets are rebounding, driven by lower interest rates and steady growth, leading to increased mergers and acquisitions as firms adapt to market changes and seek growth opportunities, particularly in fintech and private credit.

ubs maintains buy rating for johnson and johnson amid legal challenges

UBS has reaffirmed its Buy rating and $180 price target for Johnson & Johnson, despite recent legal setbacks, including a federal judge's rejection of the company's bankruptcy strategy to settle talc-related lawsuits. The firm remains optimistic about the company's potential success in traditional litigation, as Johnson & Johnson explores alternative options. Additionally, the company reported promising results from its Phase 3 MARIPOSA study for lung cancer treatments and new data on nipocalimab for myasthenia gravis, highlighting its commitment to medical advancements amid ongoing legal challenges.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.